225 related articles for article (PubMed ID: 26878994)
1. Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy.
Rombout-Sestrienkova E; Koek GH; Neslo R; van Kraaij M; Menheere PP; Masclee A; Swinkels DW
J Clin Apher; 2016 Dec; 31(6):564-570. PubMed ID: 26878994
[TBL] [Abstract][Full Text] [Related]
2. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of erythrocytapheresis and low-dose erythropoietin for treatment of hemochromatosis.
Brückl D; Kamhieh-Milz S; Kamhieh-Milz J; Salama A
J Clin Apher; 2017 Jun; 32(3):170-174. PubMed ID: 27271482
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study.
Rombout-Sestrienkova E; van Noord PA; van Deursen CT; Sybesma BJ; Nillesen-Meertens AE; Koek GH
Transfus Apher Sci; 2007 Jun; 36(3):261-7. PubMed ID: 17569592
[TBL] [Abstract][Full Text] [Related]
5. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.
Sundic T; Hervig T; Hannisdal S; Assmus J; Ulvik RJ; Olaussen RW; Berentsen S
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s84-9. PubMed ID: 24333062
[TBL] [Abstract][Full Text] [Related]
6. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial.
Rombout-Sestrienkova E; Winkens B; Essers BA; Nieman FH; Noord PA; Janssen MC; van Deursen CT; Boonen A; Reuser-Kaasenbrood EP; Heeremans J; van Kraaij M; Masclee A; Koek GH
Transfusion; 2016 Jan; 56(1):261-70. PubMed ID: 26358375
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
Poullin P; Lefèvre PA
Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
[TBL] [Abstract][Full Text] [Related]
8. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
[TBL] [Abstract][Full Text] [Related]
9. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial.
Ong SY; Gurrin LC; Dolling L; Dixon J; Nicoll AJ; Wolthuizen M; Wood EM; Anderson GJ; Ramm GA; Allen KJ; Olynyk JK; Crawford D; Ramm LE; Gow P; Durrant S; Powell LW; Delatycki MB
Lancet Haematol; 2017 Dec; 4(12):e607-e614. PubMed ID: 29195602
[TBL] [Abstract][Full Text] [Related]
10. A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.
Rombout-Sestrienkova E; Winkens B; van Kraaij M; van Deursen CTBM; Janssen MCH; Rennings AMJ; Evers D; Kerkhoffs JL; Masclee A; Koek GH
J Clin Apher; 2021 Jun; 36(3):340-347. PubMed ID: 33368569
[TBL] [Abstract][Full Text] [Related]
11. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative.
Kohan A; Niborski R; Daruich J; Rey J; Bastos F; Amerise G; Herrera R; García M; Olivera W; Santarelli MT; Avalos JS; Findor J
Vox Sang; 2000; 79(1):40-5. PubMed ID: 10971213
[TBL] [Abstract][Full Text] [Related]
12. [Erythrocytapheresis for hereditary haemochromatosis].
Rombout-Sestrienkova E; van Deursen CT; Janssen MC; van Kraaij MG; de Leeuw PW; Koek GH
Ned Tijdschr Geneeskd; 2012; 156(26):A4745. PubMed ID: 22759710
[TBL] [Abstract][Full Text] [Related]
13. Patients with hereditary hemochromatosis reach safe range of transferrin saturation sooner with erythrocytaphereses than with phlebotomies.
Rombout-Sestrienkova E; Brandts L; Koek GH; van Deursen CTBM
J Clin Apher; 2022 Feb; 37(1):100-105. PubMed ID: 34897777
[TBL] [Abstract][Full Text] [Related]
14. Blunted increase in serum hepcidin as response to oral iron in HFE-hemochromatosis.
Sangwaiya A; Manglam V; Busbridge M; Thursz M; Arnold J
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):721-4. PubMed ID: 21654321
[TBL] [Abstract][Full Text] [Related]
15. How we manage patients with hereditary haemochromatosis.
Rombout-Sestrienkova E; van Kraaij MG; Koek GH
Br J Haematol; 2016 Dec; 175(5):759-770. PubMed ID: 27723100
[TBL] [Abstract][Full Text] [Related]
16. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis.
Casanova-Esteban P; Guiral N; Andrés E; Gonzalvo C; Mateo-Gallego R; Giraldo P; Paramo JA; Civeira F
Metabolism; 2011 Jun; 60(6):830-4. PubMed ID: 20846699
[TBL] [Abstract][Full Text] [Related]
17. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis.
Bardou-Jacquet E; Philip J; Lorho R; Ropert M; Latournerie M; Houssel-Debry P; Guyader D; Loréal O; Boudjema K; Brissot P
Hepatology; 2014 Mar; 59(3):839-47. PubMed ID: 23775519
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis.
Rehácek V; Bláha M; Jirousová H; Cernohorská J; Papousek P
Acta Medica (Hradec Kralove); 2012; 55(4):180-5. PubMed ID: 23631289
[TBL] [Abstract][Full Text] [Related]
19. Decreased iron burden in overweight C282Y homozygous women: Putative role of increased hepcidin production.
Desgrippes R; Lainé F; Morcet J; Perrin M; Manet G; Jezequel C; Bardou-Jacquet E; Ropert M; Deugnier Y
Hepatology; 2013 May; 57(5):1784-92. PubMed ID: 23322654
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]